Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mesalamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.64 |
| ▸ | ALOX5 known ✓ | P09917 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | CASP1 | P29466 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 2/20 | 0.64 |
| ▸ | RECQL | P46063 | 2/20 | 0.64 |
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mesalamine SCHEMBL10492977 | 0.96 | KDM4E (0.66) | KDM4ETDP1POLBALDH1A1HPGD | |
| Mesalamine SCHEMBL15329201 | 0.96 | KDM4E (0.66) | KDM4ETDP1POLBALDH1A1HPGD | |
| Mesalamine SCHEMBL15329038 | 0.96 | KDM4E (0.66) | KDM4ETDP1POLBALDH1A1HPGD | |
| Mesalamine SCHEMBL15329060 | 0.96 | KDM4E (0.66) | KDM4ETDP1POLBALDH1A1HPGD | |
| Aminosalicylic Acid SCHEMBL29379024 | 0.83 | KDM4E (1.00) | KDM4ETDP1POLBALDH1A1HPGD | |
| Aminosalicylic Acid SCHEMBL688206 | 0.83 | KDM4E (1.00) | KDM4ETDP1POLBALDH1A1HPGD | |
| Mesalamine SCHEMBL9146031 | 0.83 | KDM4E (0.54) | KDM4ETDP1POLBALDH1A1HPGD | |
| Olsalazine SCHEMBL4096909 | 0.83 | MEN1 (0.66) | KDM4ETDP1POLBALDH1A1HPGD | |
| SCHEMBL2809848 | 0.83 | KDM4E (0.70) | KDM4ETDP1POLBALDH1A1HPGD | |
| Aminosalicylic Acid SCHEMBL84166 | 0.82 | KDM4E (0.96) | KDM4ETDP1POLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024164415-A1 | MODIFIED POSITIVE ELECTRODE MATERIAL, ELECTROCHEMICAL LITHIUM EXTRACTION ELECTRODE SHEET, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 广东邦普循环科技有限公司 | 2024-08-15 | — | — | WO | claimed |
| CN-116065200-A | Modified positive electrode material, electrochemical lithium extraction pole piece and preparation method and application thereof | 广东邦普循环科技有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-114632473-A | High-pressure kettle equipment for synthesis based on mesalazine high-pressure kettle method and preparation process | 恒诚制药集团淮南有限公司 | 2022-06-17 | — | — | CN | claimed |
| CN-113372718-A | Preparation method of high-crystallinity polyphenylene sulfide material | 宁夏清研高分子新材料有限公司 | 2021-09-10 | — | — | CN | claimed |
| CN-109721765-A | Preparation method of PET organic-inorganic composite nucleating agent | 南京工业大学 | 2019-05-07 | — | — | CN | claimed |
| CN-102731334-A | Method for preparing 5-aminosalicylic acid | HUNAN KMT GAS CO LTD | 2012-10-17 | — | — | CN | claimed |
| CN-1097011-A | A kind of medicine and preparation technology thereof who treats enteritis and ulcerative colitis | HE NAN NORMAL UNIV (CN) | 1995-01-04 | — | — | CN | claimed |
| EP-0398207-B1 | Stable liquid form of 5-aminosalicylic acid | MARION MERRELL DOW INC (US) | 1994-08-10 | — | — | EP | claimed |
| US-5010069-A | Alkali(earth) metal salt of 5-aminosalicylic acid as buffer | MARION LABORATORIES, INC. (US) | 1991-04-23 | — | — | US | claimed |
| EP-0398207-A1 | Stable liquid form of 5-aminosalicylic acid | MARION MERRELL DOW INC. (US) | 1990-11-22 | — | — | EP | claimed |
| CN-113613640-B | New use of R-enantiomer of adrenergic beta 2 receptor agonist for the treatment of inflammatory bowel disease and parenteral diseases | 谭文 | 2024-11-29 | — | — | CN | disclosed |
| CN-118787621-A | New application of R-salbutamol in treating inflammatory bowel disease and extra-intestinal diseases | 谭文 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024164415-A1 | MODIFIED POSITIVE ELECTRODE MATERIAL, ELECTROCHEMICAL LITHIUM EXTRACTION ELECTRODE SHEET, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 广东邦普循环科技有限公司 | 2024-08-15 | — | — | WO | disclosed |
| US-20240167922-A1 | TRANSPARENTIZING REAGENT AND TRANSPARENTIZING METHOD | KYOTO UNIVERSITY (JP) | 2024-05-23 | — | — | US | disclosed |
| EP-4306927-A1 | TRANSPARENTIZING REAGENT AND TRANSPARENTIZING METHOD | Kyoto University (JP) | 2024-01-17 | — | — | EP | disclosed |
| EP-0398207-B1 | Stable liquid form of 5-aminosalicylic acid | MARION MERRELL DOW INC (US) | 1994-08-10 | — | — | EP | disclosed |
| US-5010069-A | Alkali(earth) metal salt of 5-aminosalicylic acid as buffer | MARION LABORATORIES, INC. (US) | 1991-04-23 | — | — | US | disclosed |
| EP-0398207-A1 | Stable liquid form of 5-aminosalicylic acid | MARION MERRELL DOW INC. (US) | 1990-11-22 | — | — | EP | disclosed |
| EP-0236329-A1 | AMINO-SALICYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | ITAL-FARMACO S.p.A. (IT) | 1987-09-16 | — | — | EP | disclosed |
| WO-1986003199-A1 | AMINO-SALICYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | ITALFARMACO S.P.A. (IT) | 1986-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240167922-A1 | TRANSPARENTIZING REAGENT AND TRANSPARENTIZING METHOD | TST, TTR, ALB | PTGS2 2953/4885ALOX5 2030/4885KDM4E 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.